The role of choline in prostate cancer

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1548-1553

  Awwad, Hussain Mohamad ^a   Geisel, Juergen ^a   Obeid, Rima ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Choline; Methyl; Phospholipids; Prostate cancer

Indexed keywords

CHOLINE; ORGANIC CATION TRANSPORTER;

CANCER CELL; CANCER PROGNOSIS; CARCINOGENESIS; CELL FUNCTION; CHOLINE UPTAKE; DNA METHYLATION; HORMONAL THERAPY; HUMAN; HYPOXIA; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

CELL HYPOXIA; CHOLINE; HUMANS; MALE; PHOSPHOLIPIDS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84870656636     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.08.012     Document Type: Review

References (74)

1. Institute of Medicine Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline 1998, 390-422. National Academy Press, Washington, DC, USA.
2. Zeisel S.H., Mar M.H., Howe J.C., Holden J.M. Concentrations of choline-containing compounds and betaine in common foods. J Nutr 2003, 133:1302-1307.
3. Zeisel S.H., da Costa K.A. Choline: an essential nutrient for public health. Nutr Rev 2009, 67:615-623.
4. Fischer L.M., da Costa K.A., Kwock L., Stewart P.W., Lu T.S., Stabler S.P., et al. Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr 2007, 85:1275-1285.
5. Xu X., Gammon M.D., Zeisel S.H., Lee Y.L., Wetmur J.G., Teitelbaum S.L., et al. Choline metabolism and risk of breast cancer in a population-based study. FASEB J 2008, 22:2045-2052.
6. Zeisel S.H. Genetic polymorphisms in methyl-group metabolism and epigenetics: lessons from humans and mouse models. Brain Res 2008, 1237:5-11.
7. Glunde K., Bhujwalla Z.M., Ronen S.M. Choline metabolism in malignant transformation. Nat Rev Cancer 2011, 11:835-848.
8. Aboagye E.O., Bhujwalla Z.M. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59:80-84.
9. Katz-Brull R., Seger D., Rivenson-Segal D., Rushkin E., Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002, 62:1966-1970.
10. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004, 64:4270-4276.
11. Mori N., Delsite R., Natarajan K., Kulawiec M., Bhujwalla Z.M., Singh K.K. Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging 2004, 3:319-323.
12. Zeisel S.H. Dietary choline deficiency causes DNA strand breaks and alters epigenetic marks on DNA and histones. Mutat Res 2012, 733:34-38.
13. Cho E., Willett W.C., Colditz G.A., Fuchs C.S., Wu K., Chan A.T., et al. Dietary choline and betaine and the risk of distal colorectal adenoma in women. J Natl Cancer Inst 2007, 99:1224-1231.
14. Xu X., Gammon M.D., Zeisel S.H., Bradshaw P.T., Wetmur J.G., Teitelbaum S.L., et al. High intakes of choline and betaine reduce breast cancer mortality in a population-based study. FASEB J 2009, 23:4022-4028.
15. Johansson M., Van G.B., Vollset S.E., Hultdin J., Bergh A., Key T., et al. One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites. Cancer Epidemiol Biomarkers Prev 2009, 18:1538-1543.
16. Lee J.E., Giovannucci E., Fuchs C.S., Willett W.C., Zeisel S.H., Cho E. Choline and betaine intake and the risk of colorectal cancer in men. Cancer Epidemiol Biomarkers Prev 2010, 19:884-887.
17. Cho E., Holmes M., Hankinson S.E., Willett W.C. Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women. Cancer Epidemiol Biomarkers Prev 2007, 16:2787-2790.
18. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
19. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N Engl J Med 2003, 349:366-381.
20. Gann P.H. Risk factors for prostate cancer. Rev Urol 2002, 4(Suppl. 5):S3-S10.
21. Ramirez de Molina A., Rodriguez-Gonzalez A., Gutierrez R., Martinez-Pineiro L., Sanchez J., Bonilla F., et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002, 296:580-583.
22. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009, 100:1369-1372.
23. Zeisel S.H., Blusztajn J.K. Choline and human nutrition. Annu Rev Nutr 1994, 14:269-296.
24. Lin X., Tascilar M., Lee W.H., Vles W.J., Lee B.H., Veeraswamy R., et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001, 159:1815-1826.
25. Balassiano K., Lima S., Jenab M., Overvad K., Tjonneland A., Boutron-Ruault M.C., et al. Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett 2011, 311:85-95.
26. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30:445-600.
27. Nakayama M., Bennett C.J., Hicks J.L., Epstein J.I., Platz E.A., Nelson W.G., et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003, 163:923-933.
28. Kennedy E.P., Weiss S.B. The function of cytidine coenzymes in the biosynthesis of phospholipides. J Biol Chem 1956, 222:193-214.
29. Kent C. Regulation of phosphatidylcholine biosynthesis. Prog Lipid Res 1990, 29:87-105.
30. Aoyama C., Liao H., Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 2004, 43:266-281.
31. Jackowski S., Fagone P. CTP: phosphocholine cytidylyltransferase: paving the way from gene to membrane. J Biol Chem 2005, 280:853-856.
32. Karim M., Jackson P., Jackowski S. Gene structure, expression and identification of a new CTP:phosphocholine cytidylyltransferase beta isoform. Biochim Biophys Acta 2003, 1633:1-12.
33. Li Z., Vance D.E. Phosphatidylcholine and choline homeostasis. J Lipid Res 2008, 49:1187-1194.
34. Ramirez de Molina A., Gallego-Ortega D., Sarmentero J., Banez-Coronel M., Martin-Cantalejo Y., Lacal J.C. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 2005, 65:5647-5653.
35. Ramirez de Molina A., Banez-Coronel M., Gutierrez R., Rodriguez-Gonzalez A., Olmeda D., Megias D., et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004, 64:6732-6739.
36. Cao M.D., Dopkens M., Krishnamachary B., Vesuna F., Gadiya M.M., Lonning P.E., et al. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed 2012, 25:1033-1042.
37. Stewart J.D., Marchan R., Lesjak M.S., Lambert J., Hergenroeder R., Ellis J.K., et al. Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci U S A 2012, 109:8155-8160.
38. Foster D.A., Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res 2003, 1:789-800.
39. Qi C., Park J.H., Gibbs T.C., Shirley D.W., Bradshaw C.D., Ella K.M., et al. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J Cell Physiol 1998, 174:261-272.
40. Gallazzini M., Ferraris J.D., Burg M.B. GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci U S A 2008, 105:11026-11031.
41. Exton J.H. Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1994, 1212:26-42.
42. Beloueche-Babari M., Peak J.C., Jackson L.E., Tiet M.Y., Leach M.O., Eccles S.A. Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells. Mol Cancer Ther 2009, 8:1305-1311.
43. Sheard N.F., Zeisel S.H. An in vitro study of choline uptake by intestine from neonatal and adult rats. Pediatr Res 1986, 20:768-772.
44. Michel V., Yuan Z., Ramsubir S., Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood) 2006, 231:490-504.
45. Okuda T., Haga T. High-affinity choline transporter. Neurochem Res 2003, 28:483-488.
46. Tamai I., Yabuuchi H., Nezu J., Sai Y., Oku A., Shimane M., et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 1997, 419:107-111.
47. Wu X., Huang W., Prasad P.D., Seth P., Rajan D.P., Leibach F.H., et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 1999, 290:1482-1492.
48. Muller S.A., Holzapfel K., Seidl C., Treiber U., Krause B.J., Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging 2009, 36:1434-1442.
49. 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011, 38:1985-1989.
50. Giovacchini G., Picchio M., Coradeschi E., Scattoni V., Bettinardi V., Cozzarini C., et al. [(11)C] choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008, 35:1065-1073.
51. 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?. Eur J Nucl Med Mol Imaging 2011, 38:55-63.
52. Swinnen J.V., Verhoeven G. Androgens and the control of lipid metabolism in human prostate cancer cells. J Steroid Biochem Mol Biol 1998, 65:191-198.
53. Hara T., Bansal A., DeGrado T.R. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006, 33:977-984.
54. Kimbro K.S., Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006, 13:739-749.
55. Glunde K., Shah T., Winnard P.T., Raman V., Takagi T., Vesuna F., et al. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signalling in a human prostate cancer model. Cancer Res 2008, 68:172-180.
56. Keshari K.R., Tsachres H., Iman R., Delos S.L., Tabatabai Z.L., Shinohara K., et al. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR Biomed 2011, 24:691-699.
57. Husarik D.B., Miralbell R., Dubs M., John H., Giger O.T., Gelet A., et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:253-263.
58. Rinnab L., Blumstein N.M., Mottaghy F.M., Hautmann R.E., Kufer R., Hohl K., et al. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007, 99:1421-1426.
59. Scheenen T.W., Futterer J., Weiland E., van Hecke P., Lemort M., Zechmann C., et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol 2011, 46:25-33.
60. Swanson M.G., Keshari K.R., Tabatabai Z.L., Simko J.P., Shinohara K., Carroll P.R., et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 2008, 60:33-40.
61. Ramirez de Molina A., Penalva V., Lucas L., Lacal J.C. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002, 21:937-946.
62. Carnero A., Cuadrado A., del Peso L., Lacal J.C. Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells. Oncogene 1994, 9:1387-1395.
63. Lacal J.C., Moscat J., Aaronson S.A. Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature 1987, 330:269-272.
64. Yoo M.H., Woo C.H., You H.J., Cho S.H., Kim B.C., Choi J.E., et al. Role of the cytosolic phospholipase A2-linked cascade in signalling by an oncogenic, constitutively active Ha-Ras isoform. J Biol Chem 2001, 276:24645-24653.
65. Wieprecht M., Wieder T., Paul C., Geilen C.C., Orfanos C.E. Evidence for phosphorylation of CTP:phosphocholine cytidylyltransferase by multiple proline-directed protein kinases. J Biol Chem 1996, 271:9955-9961.
66. Van Putten V., Refaat Z., Dessev C., Blaine S., Wick M., Butterfield L., et al. Induction of cytosolic phospholipase A2 by oncogenic Ras is mediated through the JNK and ERK pathways in rat epithelial cells. J Biol Chem 2001, 276:1226-1232.
67. Wang T., Li J., Chen F., Zhao Y., He X., Wan D., et al. Choline transporters in human lung adenocarcinoma: expression and functional implications. Acta Biochim Biophys Sin (Shanghai) 2007, 39:668-674.
68. Lucas L., Penalva V., Ramirez de Molina A., del Peso L., Lacal J.C. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Int J Oncol 2002, 21:477-485.
69. Ryan A.J., Andrews M., Zhou J., Mallampalli R.K. c-Jun N-terminal kinase regulates CTP:phosphocholine cytidylyltransferase. Arch Biochem Biophys 2006, 447:23-33.
70. Aoyama C., Ishidate K., Sugimoto H., Vance D.E. Induction of choline kinase alpha by carbon tetrachloride (CCl4) occurs via increased binding of c-jun to an AP-1 element. Biochim Biophys Acta 2007, 1771:1148-1155.
71. Sugimoto H., Banchio C., Vance D.E. Transcriptional regulation of phosphatidylcholine biosynthesis. Prog Lipid Res 2008, 47:204-220.
72. Yuan Z., Tie A., Tarnopolsky M., Bakovic M. Genomic organization, promoter activity, and expression of the human choline transporter-like protein 1. Physiol Genomics 2006, 26:76-90.
73. Banchio C., Lingrell S., Vance D.E. Sp-1 binds promoter elements that are regulated by retinoblastoma and regulate CTP:phosphocholine cytidylyltransferase-alpha transcription. J Biol Chem 2007, 282:14827-14835.
74. Gao S., Murakami M., Ito H., Furuhata A., Yoshida K., Tagawa Y., et al. Mutated ras induced PLD1 gene expression through increased Sp1 transcription factor. Nagoya J Med Sci 2009, 71:127-136.